Clinical Plan # 1 Approval Where is the developer of a corona 19 and flu simultaneous diagnostic kit? … They take Biotech, not Seegene

Entry 2020.09.08 19:41 | Revision 2020.09.08 19:45

The government announced on the 8th that it had approved a clinical performance testing plan on the 7th for an in vitro diagnostic reagent that can simultaneously diagnose the presence of a novel coronavirus (Corona 19) infection and an influenza (flu) infection. , but did not reveal the name of the company. It aroused curiosity.

In this regard, Jung Yong-ik, head of the Ministry of Food and Drug Safety, said in a briefing on the 8th: “Clinical trial plans have been implemented for two manufacturers and three products, and one of them has been approved. “. It is a product that simultaneously tests both corona virus 19 and influenza virus by collecting samples in the same way as test 19. “However, he asked about the name of the company and the product and said:” It cannot be disclosed specifically”.

As a leader in corona 19 diagnostic kits Seegene (096530)On this day, it published a press release that it will launch a diagnostic product that can test multiple respiratory viruses such as Corona 19 and influenza at the same time on the global market starting this month. Anticipation that Seegen will lead the way for a diagnostic kit that will help prevent the double pandemic (infectious disease pandemic), where corona and flu are simultaneously epidemics, has also risen, and Seegene’s share price has increased. increased by about 7%.

However, Seegene’s share price rose 1.23% to 241,700 won, and the product was confirmed to have been developed by national company Kogen Biotech. The in vitro diagnostic reagent collects a sample in the same way as the Corona 19 test and tests for corona virus and influenza virus (A · B) at the same time. The government hopes it will be useful in diagnosing infectious diseases when it is marketed in the future, as the winter flu and Corona 19 can simultaneously be an epidemic.

The Ministry of Food and Drug Safety said: “We plan to continue to support in vitro diagnostic reagents because they require additional permission after undergoing clinical trials.”